麦肯锡：2030年医疗事务展望-影响患者的五大优先事项（中译版）（10页）.pdf

1、Life Sciences PracticeA vision for medical affairs 2030:Five priorities for patient impactIn 2018,we foresaw medical affairs playing a more strategic role and contributing greater patient impact.That future is now;theres work to be done to realize it and reach the next level vision.This article is a

2、 collaborative effort by Jeffrey Algazy,Alba Garcia,Sean Ryan,Ann Westra,and Alexandra Zemp,representing views from McKinseys Life Sciences Practice.October 2023The white paper A vision for medical affairs in 2025,published five years ago,describes a future in which innovation in digital technology

3、and biological sciences would explode at an exponential pace.Medical-affairs teams would reshape their role,delivering greater impact for patients and becoming a coequal third pillar of pharmaceutical companies alongside R&D and commercial.Today,just a few years later,the importance of medical-affai

4、rs leadership has come into even sharper focus as the industry and world have reacted to the COVID-19 pandemic,the meteoric development of mRNA vaccines,and a complete upending of the pharmaphysician engagement model.Navigating a rapidly changing landscapeThe dynamism of the industry continues.A mas

5、sive investment in sciencein 2021,biotech venture funding hit an all-time high of almost$47 billion1has fueled a robust pipeline with diverse modalities across therapeutic areas.Real-world-evidence(RWE)capabilities have advanced and scaled,with a massive proliferation of new types of data to support

6、 existing treatments.In the clinic,healthcare practitioners(HCPs)and patients have access to 75 percent more assets per indication than they did ten years ago.With more therapeutic options available,staying current with scientific literature and guidelines has become an overwhelming task for communi